Ainos submits clinical hold complete response to FDA for VELDONA Phase 2 COVID-19 trial

Ainos, Inc.

Submitted clinical hold complete response to FDA for Phase 2 trial of low-dose oral IFN-alpha VELDONA for mild COVID-19.
Phase 2 multicenter randomized study expected in Taiwan in Q3 2024 if approved.
Updated CMC and stability data show VELDONA can exceed minimum shelf life for biologicals.
Plans additional IND applications in H2 2024 for oral warts (orphan drug) and Sjögren's syndrome.
Low-dose oral VELDONA safety demonstrated in ~6,000 subjects across 68 clinical trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.